Jingsj
.mol.sdf

L-亮氨酸-3,3-d2

别名 / 同义词: L-亮氨酸-D2、L-亮氨酸-3,3-氘代、亮氨酸-3,3-d2

L-亮氨酸-3,3-d2（CAS 362049-59-0）是晶世纪化学数据库收录的有机酸。分子式为 C6H11D2NO2，分子量为 133.185 g/mol。又称 L-亮氨酸-D2、L-亮氨酸-3,3-氘代、亮氨酸-3,3-d2。主要理化性质包括沸点 225.8±23.0 °C at 760 mmHg、密度 1.0±0.1 g/cm3、闪点 90.3±22.6 °C。目前暂无供应商报价，可通过联系页询价。数据更新于 2026年8月21日。

CAS号
362049-59-0
晶世纪编号
J-1957321-8
分子式
C6H11D2NO2
分子量
133.185 g/mol
分类
有机酸
更新时间
2026/8/21

该化合物暂无报价。

获取报价

基础理化性质

沸点225.8±23.0 °C at 760 mmHg
密度1.0±0.1 g/cm3
闪点90.3±22.6 °C
精确质量133.107178
其他信息63.32000
LogP0.73
蒸汽压0.0±0.9 mmHg at 25°C
折射率1.463

活性 / 生物活性

描述L-亮氨酸-d2是氘标记的L-亮氨酸。L-亮氨酸是一种必需的支链氨基酸(BCAA),可激活mTOR信号通路[1]。
相关类别信号通路 >> PI3K/Akt/mTOR 信号通路 >> mTOR 研究领域 >> 代谢疾病
体外研究氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注[1]。
参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Rachdi L, et al. L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway. Diabetes. 2012 Feb;61(2):409-17. [3]. Baoshan Xu, et al. Stimulation of mTORC1 with L-leucine rescues defects associated with Roberts syndrome. PLoS Genet. 2013;9(10):e1003857. [4]. Rachdi L, et al. L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway. Diabetes. 2012 Feb;61(2):409-17. [5]. Rachdi L, et al. L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway. Diabetes. 2012 Feb;61(2):409-17. [6]. Rachdi L, et al. L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway. Diabetes. 2012 Feb;61(2):409-17. [7]. Rachdi L, et al. L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway. Diabetes. 2012 Feb;61(2):409-17. [8]. Rachdi L, et al. L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway. Diabetes. 2012 Feb;61(2):409-17. [9]. Rachdi L, et al. L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway. Diabetes. 2012 Feb;61(2):409-17. [10]. Rachdi L, et al. L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway. Diabetes. 2012 Feb;61(2):409-17. [11]. Bruckbauer A, et al. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond). 2012 Aug 22;9(1):77. [12]. Baoshan Xu, et al. Stimulation of mTORC1 with L-leucine rescues defects associated with Roberts syndrome. PLoS Genet. 2013;9(10):e1003857. [13]. Baoshan Xu, et al. Stimulation of mTORC1 with L-leucine rescues defects associated with Roberts syndrome. PLoS Genet. 2013;9(10):e1003857. [14]. Baoshan Xu, et al. Stimulation of mTORC1 with L-leucine rescues defects associated with Roberts syndrome. PLoS Genet. 2013;9(10):e1003857. [15]. Baoshan Xu, et al. Stimulation of mTORC1 with L-leucine rescues defects associated with Roberts syndrome. PLoS Genet. 2013;9(10):e1003857. [16]. Baoshan Xu, et al. Stimulation of mTORC1 with L-leucine rescues defects associated with Roberts syndrome. PLoS Genet. 2013;9(10):e1003857. [17]. Baoshan Xu, et al. Stimulation of mTORC1 with L-leucine rescues defects associated with Roberts syndrome. PLoS Genet. 2013;9(10):e1003857. [18]. Baoshan Xu, et al. Stimulation of mTORC1 with L-leucine rescues defects associated with Roberts syndrome. PLoS Genet. 2013;9(10):e1003857. [19]. Bruckbauer A, et al. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond). 2012 Aug 22;9(1):77. [20]. Bruckbauer A, et al. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond). 2012 Aug 22;9(1):77. [21]. Bruckbauer A, et al. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond). 2012 Aug 22;9(1):77. [22]. Bruckbauer A, et al. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond). 2012 Aug 22;9(1):77. [23]. Bruckbauer A, et al. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond). 2012 Aug 22;9(1):77. [24]. Bruckbauer A, et al. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond). 2012 Aug 22;9(1):77. [25]. Bruckbauer A, et al. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond). 2012 Aug 22;9(1):77.

常见问题

L-亮氨酸-3,3-d2 的 CAS 号是多少？

L-亮氨酸-3,3-d2 的 CAS 号是 362049-59-0。

L-亮氨酸-3,3-d2 的分子式和分子量是什么？

L-亮氨酸-3,3-d2 的分子式为 C6H11D2NO2，分子量为 133.185 g/mol。

数据来自公开化学数据库与供应商目录；供应商报价由供应商提供。

更新时间:

引用格式: 晶世纪. “L-亮氨酸-3,3-d2 (CAS 362049-59-0)”. 晶世纪化学数据库. https://www.jingsj.com/zh/compound/J-1957321-8（访问日期：2026-10-26）。

数据仅供参考；采购前请与供应商核实规格、等级与法规状态。